Literature DB >> 19861949

Long-term physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructs.

Olivia C Hibbitt1, Eileen McNeil, Michele Mp Lufino, Len Seymour, Keith Channon, Richard Wade-Martins.   

Abstract

Familial hypercholesterolemia (FH) is a condition caused by mutations in the low-density lipoprotein receptor (LDLR) gene. Expression of LDLR is highly regulated and excess receptor expression is cytotoxic. To incorporate essential gene regulation into a gene therapy vector for FH, we generated vectors in which the expression of therapeutic human LDLR gene, or luciferase reporter gene, is driven by 10 kb of human LDLR genomic DNA encompassing the promoter region including elements essential for physiologically regulated expression. Using luciferase expression and specific LDL binding and internalization assays, we have shown in vitro that the genomic promoter element confers long-term, physiologically regulated gene expression and complementation of receptor deficiency in culture for 240 cell-generations. This was demonstrated in the presence of sterols or statins, modifiers of LDLR promoter activity. In vivo, we demonstrate efficient liver-specific delivery and expression of luciferase following hydrodynamic tail-vein injection and confirm that expression from the LDLR promoter element is sensitive to statin administration. We also demonstrate long-term LDLR expression from the 10-kb promoter element up to 9 months following delivery. The vector system that we describe provides the efficient delivery, long-term expression, and physiological regulation required for a successful gene therapy intervention for FH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861949      PMCID: PMC2839284          DOI: 10.1038/mt.2009.249

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  42 in total

1.  High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA.

Authors:  G Zhang; V Budker; J A Wolff
Journal:  Hum Gene Ther       Date:  1999-07-01       Impact factor: 5.695

2.  [Hydrodynamics-based transfer of human apolipoprotein A-I gene into mice: study of factors involving an efficacy and duration of the transferred gene expression in animals' liver].

Authors:  B N Ajuf'ev; E B Dizhe; A M Efremov; D A Mogilenko; G N Oleĭnikova; I A Lapikov; O Iu Zhdanova; O V Kidgotko; S V Orlov; A P Perevozchikov
Journal:  Mol Biol (Mosk)       Date:  2004 Nov-Dec

3.  Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume.

Authors:  H Yoshino; K Hashizume; E Kobayashi
Journal:  Gene Ther       Date:  2006-07-27       Impact factor: 5.250

4.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.

Authors:  F Liu; Y Song; D Liu
Journal:  Gene Ther       Date:  1999-07       Impact factor: 5.250

5.  Pig liver gene therapy by noninvasive interventionist catheterism.

Authors:  S F Aliño; M J Herrero; I Noguera; F Dasí; M Sánchez
Journal:  Gene Ther       Date:  2006-10-12       Impact factor: 5.250

6.  Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment.

Authors:  Jason Johnson; Kevin Carson; Helen Williams; Sharada Karanam; Andrew Newby; Gianni Angelini; Sarah George; Christopher Jackson
Journal:  Circulation       Date:  2005-03-22       Impact factor: 29.690

7.  Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava.

Authors:  J W Fabre; A Grehan; M Whitehorne; G J Sawyer; X Dong; S Salehi; L Eckley; X Zhang; M Seddon; A M Shah; M Davenport; M Rela
Journal:  Gene Ther       Date:  2007-11-15       Impact factor: 5.250

Review 8.  Delivery of large genomic DNA inserts >100 kb using HSV-1 amplicons.

Authors:  Olivia C Hibbitt; Richard Wade-Martins
Journal:  Curr Gene Ther       Date:  2006-06       Impact factor: 4.391

9.  An S/MAR-based infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency.

Authors:  Michele M P Lufino; Roberto Manservigi; Richard Wade-Martins
Journal:  Nucleic Acids Res       Date:  2007-08-02       Impact factor: 16.971

10.  Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection.

Authors:  Olivia C Hibbitt; Richard P Harbottle; Simon N Waddington; Christine A Bursill; Charles Coutelle; Keith M Channon; Richard Wade-Martins
Journal:  J Gene Med       Date:  2007-06       Impact factor: 4.565

View more
  14 in total

1.  Slouching towards gene therapy for hypercholesterolemia.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2011-06       Impact factor: 4.599

Review 2.  Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia.

Authors:  Ezim Ajufo; Marina Cuchel
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

3.  Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies.

Authors:  Sadik H Kassim; James M Wilson; Daniel J Rader
Journal:  Clin Lipidol       Date:  2010-06

4.  Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis.

Authors:  Sadik H Kassim; Hui Li; Luk H Vandenberghe; Christian Hinderer; Peter Bell; Dawn Marchadier; Aisha Wilson; Debra Cromley; Valeska Redon; Hongwei Yu; James M Wilson; Daniel J Rader
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

Review 5.  Optimal management of familial hypercholesterolemia: treatment and management strategies.

Authors:  Mohammad Hassan Nemati; Behrooz Astaneh
Journal:  Vasc Health Risk Manag       Date:  2010-12-03

6.  Construction of minicircle DNA vectors capable of correcting familial hypercholesterolemia phenotype in a LDLR-deficient mouse model.

Authors:  X Hou; R Jiao; X Guo; T Wang; P Chen; D Wang; Y Chen; C-Y He; Z-Y Chen
Journal:  Gene Ther       Date:  2016-04-19       Impact factor: 5.250

7.  LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives.

Authors:  Faisal A Al-Allaf; Charles Coutelle; Simon N Waddington; Anna L David; Richard Harbottle; Michael Themis
Journal:  Int Arch Med       Date:  2010-12-13

8.  Cohort Generation and Characterization of Patient-Specific Familial Hypercholesterolemia Induced Pluripotent Stem Cells.

Authors:  Linda Omer; Elizabeth A Hudson; Lisa C Hudgins; Nolan L Boyd
Journal:  Stem Cells Dev       Date:  2021-05-21       Impact factor: 4.390

9.  Restoration of Physiologically Responsive Low-Density Lipoprotein Receptor-Mediated Endocytosis in Genetically Deficient Induced Pluripotent Stem Cells.

Authors:  Venkat M Ramakrishnan; Jeong-Yeh Yang; Kevin T Tien; Thomas R McKinley; Braden R Bocard; John G Maijub; Patrick O Burchell; Stuart K Williams; Marvin E Morris; James B Hoying; Richard Wade-Martins; Franklin D West; Nolan L Boyd
Journal:  Sci Rep       Date:  2015-08-26       Impact factor: 4.379

10.  Endogenous ceramide contributes to the transcytosis of oxLDL across endothelial cells and promotes its subendothelial retention in vascular wall.

Authors:  Wenjing Li; Xiaoyan Yang; Shasha Xing; Fang Bian; Wanjing Yao; Xiangli Bai; Tao Zheng; Guangjie Wu; Si Jin
Journal:  Oxid Med Cell Longev       Date:  2014-04-10       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.